Symphogen A/S of Denmark has raised an additional €41 million from private investors towards the development of its portfolio of compounds in oncology which are antibody mixture products addressing multiple targets in a single product. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
